Recombinant Human FGF7

Catalog Number: 923-FG7



DESCRIPTION

Background:

FGF-7 (fibroblast growth factor-7) is one of 22 known members of the mouse FGF family of secreted proteins that plays a key role in development, morphogenesis, angiogenesis, wound healing, and tumorigenesis [1].FGF-7 promotes cell migration and invasion, and mediates melanocyte transfer to keratinocytes upon UVB radiation [2]. It has been used ectopically to avoid chemotherapy-induced oral mucositis in patients with hematological malignancies. Deletion of FGF-7 affects kidney development, producing abnormally small ureteric buds and fewer nephrons [3]. It also impedes hair follicle differentiation [4]. The 194 amino acid (aa) FGF-7 precursor contains a 31 aa signal sequence and, like all other FGFs, an ~120 aa beta -trefoil scaffold that includes receptor- and heparin-binding sites.

Source:

Chinese Hamster Ovary cell line

Protein Construction:

A DNA sequence encoding the amino acids (Cys32-Thr194) of human FGF-7 (Accession Number:

P21781) was expressed.

Synonyms:

HBGF-7; Heparin-binding growth factor 7; keratinocyte growth factor; KGF.

SPECIFICATIONS

Purity:

≥ 95%, by SDS-PAGE visualized with quantitative densitometry by Coomassie[®] Blue Staining.

Biological Activity:

Measured in CellTiter-Glo 3D Cell Viability Assay using human bronchoalveolar organoids. The ED50 for this effect is 5-10 ng/ml.

Endotoxin Level:

<0.10 EU per 1 μg of the protein by the LAL method

Calculated Molecular Weight:

19 kDa

SDS-PAGE:

22 kDa, reducing conditions

Recombinant Human FGF7





DATA



FORMULATION AND STORAGE

Formulation:

The product is Lyophilized from a 0.22 µm filtered solution in PBS.

Shipping:

The product is shipped on ice. Upon receipt, store it immediately as methods recommended below.

Reconstitution:

Reconstitute in sterile PBS buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL.

Stability & Storage:

24 months, -20 to -70 °C, under powder state; 12 months, -20 to -70 °C, under sterile conditions after reconstitution; 2 month, 2 to 8 °C under sterile conditions after reconstitution; avoid repeated freeze-thaw cycles.

References:

- Finch, P.W. and J.S. Rubin, Keratinocyte growth factor expression and activity in cancer: implications for use 1. in patients with solid tumors. J Natl Cancer Inst, 2006. 98(12)
- 2. Niu, J., et al., Keratinocyte growth factor/fibroblast growth factor-7-regulated cell migration and invasion through activation of NF-kappaB transcription factors. J Biol Chem, 2007. 282(9)
- 3. Qiao, J., et al., FGF-7 modulates ureteric bud growth and nephron number in the developing kidney. Development, 1999. 126(3)
- 4. Guo, L., L. Degenstein, and E. Fuchs, Keratinocyte growth factor is required for hair development but not for wound healing. Genes Dev, 1996. 10(2):